A phase II study of infigratinib in previously treated advanced/metastatic cholangiocarcinoma with FGFR gene fusions/alterations

被引：3

作者：

Javle, Milind M. ^{[1
]}

Kelley, Robin Kate ^{[2
]}

Springfeld, Christoph ^{[3
]}

Abou-Alfa, Ghassan K. ^{[4
]}

Macarulla, Teresa ^{[5
]}

Tanasanvimon, Suebpong ^{[6
]}

Goyal, Lipika ^{[7
]}

Borbath, Ivan ^{[8
]}

Bitzer, Michael ^{[9
]}

Yong, Wei-Peng ^{[10
]}

Philip, Philip Agop ^{[11
]}

Alvarez-Gallego, Rafael ^{[12
]}

Pande, Amit ^{[13
]}

Shepherd, Stacie Peacock ^{[13
]}

Fontaine, Jacki ^{[13
]}

Roychowdhury, Sameek ^{[14
]}

机构：

[1] MD Anderson Canc Ctr, Houston, TX USA

[2] Univ Calif San Francisco, San Francisco, CA 94143 USA

[3] Natl Ctr Tumor Dis Heidelberg, Heidelberg, Germany

[4] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[5] Hosp Valle De Hebron, Barcelona, Spain

[6] Chulalongkorn Univ, Bangkok, Thailand

[7] Massachusetts Gen Hosp, Boston, MA 02114 USA

[8] Clin Univ St Luc, Brussels, Belgium

[9] Univ Hosp Tubingen, Tubingen, Germany

[10] Natl Univ Canc Inst Singapore, Singapore, Singapore

[11] Karmanos Canc Inst, Detroit, MI USA

[12] CIOCC HM Sanchinarro Hosp, Madrid, Spain

[13] QED Therapeut, San Francisco, CA USA

[14] Ohio State Comprehens Canc Ctr, James Canc Hosp, Columbus, OH USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 03期

关键词：

D O I：

10.1200/JCO.2021.39.3_suppl.TPS356

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS356

引用

页数：2

共 50 条

[1] Infigratinib for the Treatment of Metastatic or Locally Advanced Cholangiocarcinoma With Known FGFR2 Gene Fusions or Rearrangements
White, Kathryn
Anwar, Ahmed I.
Jin, Kevin
Bollich, Victoria
Kelkar, Rucha A.
Talbot, Norris C.
Klapper, Rachel J.
Ahmadzadeh, Shahab
Viswanath, Omar
Varrassi, Giustino
Shekoohi, Sahar
Kaye, Alan D.
CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (10)
[2] Pemigatinib in previously treated Chinese patients with locally advanced or metastatic cholangiocarcinoma carrying FGFR2 fusions or rearrangements: A phase II study
Shi, Guo-Ming
Huang, Xiao-Yong
Wen, Tian-Fu
Song, Tian-Qiang
Kuang, Ming
Mou, Hai-Bo
Bao, Le-Qun
Zhao, Hai-Tao
Zhao, Hong
Feng, Xie-Lin
Zhang, Bi-Xiang
Peng, Tao
Zhang, Yu-Bao
Li, Xiang-Cheng
Yu, Hong-Sheng
Cao, Yu
Liu, Lian-Xin
Zhang, Ti
Wang, Wei-Lin
Ran, Jiang-Hua
Liu, Ying-Bin
Gong, Wei
Chen, Ming-Xia
Cao, Lian
Luo, Yang
Wang, Yan
Zhou, Hui
Yang, Guo-Huan
Fan, Jia
Zhou, Jian
CANCER MEDICINE, 2023, 12 (04): : 4137 - 4146
[3] Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions
Javle, M.
Kelley, R. K.
Roychowdhury, S.
Weiss, K. H.
Abou-Alfa, G. K.
Macarulla, T.
Sadeghi, S.
Waldschmidt, D.
Zhu, A. X.
Goyal, L.
Borad, M.
Yong, W. P.
Borbath, I.
El-Khoueiry, A.
Philip, P.
Moran, S.
Ye, Y.
Ising, M.
Lewis, N.
Bekaii-Saab, T.
ANNALS OF ONCOLOGY, 2018, 29 : 720 - 720
[4] Pemigatinib for adults with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions/rearrangements
Walden, Daniel
Eslinger, Cody
Bekaii-Saab, Tanios
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY, 2022, 15
[5] Infigratinib in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: the PROOF 301 trial
Makawita, Shalini
Abou-Alfa, Ghassan K.
Roychowdhury, Sameek
Sadeghi, Saeed
Borbath, Ivan
Goyal, Lipika
Cohn, Allen
Lamarca, Angela
Oh, Do-Youn
Macarulla, Teresa
Shroff, Rachna T.
Howland, Michael
Li, Ai
Cho, Terry
Pande, Amit
Javle, Milind
FUTURE ONCOLOGY, 2020, 16 (30) : 2375 - 2384
[6] Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study
Javle, Milind
Roychowdhury, Sameek
Kelley, Robin Kate
Sadeghi, Saeed
Macarulla, Teresa
Weiss, Karl Heinz
Waldschmidt, Dirk-Thomas
Goyal, Lipika
Borbath, Ivan
El-Khoueiry, Anthony
Borad, Mitesh J.
Yong, Wei Peng
Philip, Philip A.
Bitzer, Michael
Tanasanvimon, Surbpong
Li, Ai
Pande, Amit
Soifer, Harris S.
Shepherd, Stacie Peacock
Moran, Susan
Zhu, Andrew X.
Bekaii-Saab, Tanios S.
Abou-Alfa, Ghassan K.
LANCET GASTROENTEROLOGY & HEPATOLOGY, 2021, 6 (10): : 803 - 815
[7] Final results from a phase II study of infigratinib (BGJ398), an FGFR-selective tyrosine kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement.
Javle, Milind M.
Roychowdhury, Sameek
Kelley, Robin Kate
Sadeghi, Saeed
Macarulla, Teresa
Waldschmidt, Dirk Thomas
Goyal, Lipika
Borbath, Ivan
El-Khoueiry, Anthony B.
Yong, Wei-Peng
Philip, Philip Agop
Bitzer, Michael
Tanasanvimon, Suebpong
Li Ai
Pande, Amit
Shepherd, Stacie Peacock
Moran, Susan
Abou-Alfa, Ghassan K.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
[8] Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study
Lassman, Andrew B.
Sepulveda-Sanchez, Juan Manuel
Cloughesy, Timothy F.
Gil-Gil, Miguel J.
Puduvalli, Vinay K.
Raizer, Jeffrey J.
De Vos, Filip Y. F.
Wen, Patrick Y.
Butowski, Nicholas A.
Clement, Paul M. J.
Groves, Morris D.
Belda-Iniesta, Cristobal
Giglio, Pierre
Soifer, Harris S.
Rowsey, Steven
Xu, Cindy
Avogadri, Francesca
Wei, Ge
Moran, Susan
Roth, Patrick
CLINICAL CANCER RESEARCH, 2022, 28 (11) : 2270 - 2277
[9] Gunagratinib, a highly selective irreversible FGFR inhibitor, in patients with previously treated locally advanced or metastatic cholangiocarcinoma harboring FGFR pathway alterations: A phase IIa dose-expansion study.
Guo, Ye
Yuan, Chunwang
Ding, Weimin
Gao, Yi
Zhu, Xu
Ying, Jieer
Sun, Meili
Zhang, Jingdong
Zhuang, Zhixiang
Huang, Yangqing
Deng, Lichun
Chen, Ping
Bai, Yuxian
Niu, Zuoxing
Li, Wei
Yin, Xiaoyu
Xu, Aibing
Cheng, Yufeng
Li, Jin
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 572 - 572
[10] A phase 2 study of HMPL-453, a selective FGFR tyrosine kinase inhibitor (TKI), in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions
Xu, Jianming
Xiong, Jianping
Gu, Shanzhi
Niu, Zuoxing
Yin, Fei
Sun, Beicheng
Zhang, Lan
Zhou, Fuxiang
Hao, Chunyi
Pan, Yueyin
Qiu, Wensheng
Gao, Yi
Ren, Yongxin
Fan, Songhua
Shi, Michael
Su, Weiguo
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

← 1 2 3 4 5 →